<DOC>
	<DOC>NCT00414440</DOC>
	<brief_summary>This study will assess whether everolimus (RAD001) is effective in preventing cyst and kidney expansion as well as worsening of renal function in patients with ADPKD and whether the application of 5 mg/day everolimus as monotherapy is safe and well tolerated.</brief_summary>
	<brief_title>Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion Criteria 1. Clinical diagnosis of autosomal dominant polycystic kidney disease ADPKD 2. Chronic kidney disease (CKD) stage II / III 3. Females capable of becoming pregnant must have a negative serum pregnancy test within 7 days prior to or at baseline, and are required to practice an approved method of birth control for the duration of the study and for a period of 6 weeks following discontinuation of study medication, even where there has been a history of infertility Exclusion Criteria 1. ADPKD patients with normal renal function 2. ADPKD patients with CKD stage IV 3. Patients with a history of subarachnoid bleeding 4. Patients with a history of severe infections 5. Patients with lifethreatening urinary tract or cyst infection in the past 6. Patients who have received any investigational drug within four weeks prior to baseline 7. Patients who have been treated with any nonprotocol immunosuppressive drug or treatment within one month prior to baseline Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>end-stage renal disease, ESRD, autosomal dominant polycystic kidney disease, ADPKD, everolimus</keyword>
</DOC>